335 completed, 81 unknown, 52 recruiting, 37 not yet recruiting. 588 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 588 | Completed 335, Unknown 81, Recruiting 52, Not yet recruiting 37, Terminated 33, Active not recruiting 25, Withdrawn 20, Enrolling by invitation 4, Suspended 1 |
Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Community Active and Healthy Families Pragmatic Trial Community Active and Healthy Families Intensive Health Behavior and Lifestyle Treatment - Child Obesity | Phase 4 | Not yet recruiting | University of Colorado, Denver | 416 | 2028-01-01 | 2026-10-09 |
| Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access Semaglutide, Virtual Weight Management Coaching - Obesity, Chronic Kidney Disease | Phase 4 | Not yet recruiting | Kristin Clemens | 880 | 2027-01-01 | 2026-10-05 |
| SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer GLP-1 Receptor Agonist, Levonorgestrel IUD (Lng-IUD), Oral Progestins - Endometrial Cancer, Endometrial Cancer Stage I | Phase 4 | Not yet recruiting | Hospital Universitari de Bellvitge | 80 | 2027-01-01 | 2026-06-10 |
| Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose - Obesity & Overweight, Cardiometabolic Health Indicators | Phase 4 | Not yet recruiting | Jing Luo | 60 | 2026-12-01 | 2026-11-03 |
| GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward Semaglutide - Obesity, Childhood | Phase 4 | Not yet recruiting | University of Minnesota | 1020 | 2026-11-15 | 2026-10-20 |
| Metabolic Surgery for Atrial Fibrillation Elimination Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment - Atrial Fibrillation, Obesity and Obesity-related Medical Conditions | Phase 4 | Not yet recruiting | Ali Aminian | 100 | 2026-11-01 | 2026-04-17 |
| Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation Phentermine Pill, Orforglipron - Obesity | Phase 4 | Not yet recruiting | Massachusetts General Hospital | 60 | 2026-11-01 | 2026-07-27 |
| Mechanisms of Weight Loss: Tirzepatide vs Semaglutide Tirzepatide, Semaglutide - Obesity (Disorder) | Phase 4 | Recruiting | McMaster University | 80 | 2026-10-31 | 2026-10-28 |
| Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity Placebo, Tirzepatide - Obese Adults | Phase 4 | Not yet recruiting | Mayo Clinic | 30 | 2026-10-26 | 2026-10-26 |
| Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss semaglutide - Class I/II Obesity | Phase 4 | Recruiting | Alain Dagher | 240 | 2026-10-21 | 2026-10-26 |
| Semaglutide in Youth With Autism Spectrum Disorder Glucagon-like peptide-1 receptor agonist：Semaglutide, Lifestyle Management (LSM) Counseling - Autism Spectrum Disorder, Obesity | Phase 4 | Recruiting | Children's Hospital Medical Center, Cincinnati | 42 | 2026-10-18 | 2026-11-09 |
| Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide Dual GIP/GLP-1 Receptor Agonist Tirzepatide, Resistance Training - Obesity (BMI>30) | Phase 4 | Recruiting | Technical University of Munich | 150 | 2026-10-07 | 2026-10-20 |
| Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery Semaglutide weekly injection, Placebo - Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 100 | 2026-10-01 | 2026-10-05 |
| Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain Semaglutide weekly injection, Placebo - Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 100 | 2026-10-01 | 2026-10-05 |
| Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher Semaglutide weekly injection, Placebo - Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 100 | 2026-10-01 | 2026-10-05 |
| TRPTI Metabolic and GLP-1 Pharmacodynamic Study TRPTI, Placebo - Overweight , Obesity | Phase 4 | Not yet recruiting | RDC Clinical Pty Ltd | 20 | 2026-10-01 | 2026-09-30 |
| Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE) Semaglutide weekly injection, Placabo - Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 104 | 2026-10-01 | 2026-10-05 |
| GLP-1s in Hip and Knee Arthroplasty GLP-1 Receptor Agonists + Behavioral modification, Behavioral + placebo - Arthritis, Obesity & Overweight | Phase 4 | Not yet recruiting | Nova Scotia Health Authority | 100 | 2026-10-01 | 2026-08-10 |
| Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery Semaglutide weekly injection, Placebo - Morbid Obesity | Phase 4 | Not yet recruiting | General Committee of Teaching Hospitals and Institutes, Egypt | 100 | 2026-10-01 | 2026-10-05 |
| FutureShape Family Family Care, Standard Care, Semaglutide (administered by PDS290 pen-injector) - Obesity, Overweight | Phase 4 | Recruiting | Signe Torekov | 400 | 2026-10-01 | 2026-10-29 |
Showing 20 of 588. Sign in to see all of them.
Obesity (499) · Diabetes Mellitus, Type 2 (68) · Weight Loss (58) · Obesity, Morbid (57) · Insulin Resistance (37) · Diabetes Mellitus (30) · Metabolic Syndrome (30) · Hypertension (29) · Pediatric Obesity (26) · Cardiovascular Diseases (16) · Glucose Intolerance (14) · Body Weight (13) · Obesity, Abdominal (13) · Polycystic Ovary Syndrome (13)
Nutritional and Metabolic Diseases (588) · Nutrition Disorders (586) · Overnutrition (586) · Pathological Conditions, Signs and Symptoms (583) · Signs and Symptoms (581) · Body Weight (570) · Metabolic Diseases (158) · Glucose Metabolism Disorders (148) · Endocrine System Diseases (126) · Diabetes Mellitus (73) · Obesity (73) · Body Weight Changes (64) · Hyperinsulinism (59) · Cardiovascular Diseases (49)
Liraglutide (49) · semaglutide (43) · Metformin (41) · Tirzepatide (29) · Phentermine (16) · Sodium Chloride (14) · Orlistat (12) · Diet (11) · Exenatide (11) · Qsymia (11) · Exercise (10) · Propofol (10) · bupropion hydrochloride, naltrexone hydrochoride drug combination (10) · Injections (9) · Sugars (9)
Mayo Clinic (16) · University Medical Centre Ljubljana (12) · The Cleveland Clinic (7) · Universitaire Ziekenhuizen KU Leuven (7) · Texas Tech University Health Sciences Center (6) · University of Colorado, Denver (6) · University of Pennsylvania (6) · Weill Medical College of Cornell University (6) · Yale University (6) · General Committee of Teaching Hospitals and Institutes, Egypt (5) · Hvidovre University Hospital (5) · Radboud University Medical Center (5) · Beth Israel Deaconess Medical Center (4) · Brigham and Women's Hospital (4) · Columbia University (4)
United States (220) · Canada (34) · China (30) · Denmark (24) · Italy (21) · Netherlands (21) · France (17) · Mexico (16) · Germany (14) · United Kingdom (12) · Belgium (10) · Brazil (10) · Egypt (10) · Poland (10) · Australia (9)
Ronald Hall, PharmD, MSCS (5) · Andrej Janez, MD, PhD (4) · Jan Tack (4) · Ali Aminian, MD (3) · Eda Vrtacnik Bokal, professor (3) · Holly Wyatt, MD (3) · James Hill, PhD (3) · Samuel Klein, MD (3) · Tania S Burgert, MD (3) · Adrian Vella, MD (2) · Alison Edelman, MD, MPH (2) · Andrej Janez, MD PhD (2)
PMID 15321413, PMID 16443140, PMID 18173431, PMID 19447599, PMID 19672175, PMID 20011857, PMID 20455872, PMID 21307769, PMID 21334503, PMID 21334504, PMID 22108086, PMID 22326199, PMID 22813360, PMID 23135692, PMID 23262963, PMID 23969793, PMID 23997449, PMID 24034832, PMID 24946047, PMID 25146109, PMID 25201313, PMID 25821536, PMID 25936783, PMID 26692415, PMID 26694495, PMID 27574464, PMID 27629425, PMID 27870737, PMID 28143456, PMID 8267196, PMID 10527182, PMID 11010931, PMID 11282917, PMID 11454256, PMID 11502778, PMID 11696118, PMID 11836290, PMID 12046553, PMID 12195709, PMID 12540646, PMID 12550060, PMID 12590412, PMID 14688154, PMID 15459601, PMID 15482620, PMID 15853597, PMID 15867308, PMID 16112958, PMID 16481154, PMID 16539090
5UL1RR024982-02 (5), 2015 (3), 2017 (3), 2019 (2), 2023 (2), 2025 (2), R01AT001103 (2), R01DK067071 (2), U54AG062319 (2), UL1TR000135 (2), 2005 (1), 2008 (1), 2009 (1), 2014 (1), 2016 (1)